In this study, through network pharmacology and experimental evidence, we have demonstrated that naringenin exerts therapeutic effects on cervical cancer via multiple mechanisms, including the inhibition of proliferation, migration and invasion through the regulation of the EGFR/PI3K/AKT/mTOR pathway. The gene discussed is MTOR; the disease is cervical cancer.